TABLE 3.
Effects of L-Nys on parameters of hepatic and metabolic function as determined by analysis of serum in comparison to the effects of no treatment or treatment with either D-AmB or Flu
| Treatment group | Bilirubin concn (mg/dl) | Alk.Phos. concn (U/liter) | ALT concn (U/liter) | AST concn (U/liter) | Albumin concn (g/dl) | Triglyceride concn (mg/dl) | Cholesterol concn (mg/dl) |
|---|---|---|---|---|---|---|---|
| Controls | 0.98 ± 0.19 (0.14–1.65) | 38.7 ± 7.9 (8–69) | 166.8 ± 36.2 (68–396) | 218.8 ± 47.8 (70–454) | 2.21 ± 0.14 (1.60–2.70) | 257.8 ± 35.7 (82–398) | 110.7 ± 9.3 (75–146) |
| D-AmB | 0.15 ± 0.00b (0.11–0.19) | 41.1 ± 5.0 (23–62) | 33.2 ± 18.6b (8–163) | 83.1 ± 73.5 (6–598) | 3.30 ± 0.19b (2.60–4.10) | 193.1 ± 26.1 (56–312) | 137.2 ± 9.2 (108–191) |
| Flu | 0.16 ± 0.00b (0.12–0.20) | 41.5 ± 6.5 (18–63) | 37.6 ± 7.5b (20–84) | 33.7 ± 19.5 (10–170) | 3.63 ± 0.13b (3.10–4.10) | 53.8 ± 7.1bc (32–89) | 110.3 ± 10.5 (73–156) |
| L-Nys2 | 0.15 ± 0.00b (0.13–0.18) | 38.2 ± 3.75 (14–47) | 27.5 ± 3.7b (15–41) | 10.8 ± 1.7d (6–22) | 3.34 ± 0.16b (2.50–3.90) | 81.5 ± 21.5b (26–221) | 117.2 ± 14.0 (67–169) |
| L-Nys4 | 0.18 ± 0.01b (0.12–0.23) | 42.6 ± 6.7 (20–77) | 22.0 ± 2.6b (11–35) | 8.2 ± 0.5e (6–10) | 3.51 ± 0.18b (2.40–4.00) | 115.1 ± 21.8ef (45–234) | 119.6 ± 14.0 (59–156) |
| Normal values | 0.11 ± 0.00 (0.10–0.19) | 108 ± 6.6 (64–235) | 43 ± 5.8 (20–163) | 16 ± 2.0 (8–45) | 3.93 ± 0.11 (3.40–6.40) | 46 ± 2.66 (25–79) | 44 ± 2.05 (29–67) |
a
All values represent the means ± SEMs for eight rabbits each; Normal values (means ± SEMs) are derived from 24 healthy, catheterized rabbits. Values in parentheses are ranges. ALT, alanine aminotransferase; AST, aspartate aminotransferase; Alk.Phos. alkaline phosphatase. ALL P values were determined by ANOVA and Bonferroni’s correction for multiple comparisons.
b
P < 0.001 versus untreated controls.
c
P < 0.01 versus D-AmB-treated animals.
d
P < 0.05 versus untreated controls.
e
P < 0.0 versus untreated controls.
f
P < 0.05 versus D-AmB-treated animals.